/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Estrella Immunopharma Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.71 0.0886(8.86%) ESLA at 04 Dec 2025 04:31 PM Biotechnology
Lowest Today 1.525
Highest Today 1.74
Today’s Open 1.63
Prev. Close 1.58
52 Week High 3.15
52 Week Low 0.73
Day’s Range: Low 1.525 High 1.74
52-Week Range: Low 0.73 High 3.15
1 day return -
1 Week return -19.62
1 month return -24.89
3 month return +65.38
6 month return +77.31
1 year return +54.95
3 year return -83.07
5 year return -
10 year return -

Institutional Holdings

Market Status

Strong Buy: 1

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 81.54 M

PB Ratio 241.3035

PE Ratio 0.0

Enterprise Value 66.35 M

Total Assets 3.14 M

Volume 243573

Company Financials

Annual Revenue FY24:null 0.0M

Annual Profit FY24:null 0.0M

Annual Net worth FY24:-7311723 -7.3M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:null 0.0M, Q1/2025:null 0.0M, Q3/2024:null 0.0M, Q2/2024:null 0.0M

Quarterly Net worth Q3/2025:-4801149 -4.8M, Q2/2025:-5544878 -5.5M, Q1/2025:-2104311 -2.1M, Q3/2024:-3376737 -3.4M, Q2/2024:-3951072 -4.0M

Fund house & investment objective

Company Information Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.

Organisation Biotechnology

Employees 0

Industry Biotechnology

CEO Dr. Cheng Liu Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow